CGTX net incomeQ3 2026-$4.14M
CGTX net income was -$4.14M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$4.93M a year earlier. For the full fiscal 2025 it was -$23.49M, compared with -$33.97M in fiscal 2024.
Cognition Therapeutics Inc. (CGTX) financials
For the twelve months ended Sep 30, 2026, Cognition Therapeutics Inc. reported -$15.99M of net income.
- Net income, TTM
- -$15.99M
- Cash
- $30.76M
- Market cap
- $65.3M
FY2020FY2025
FY2020FY2024
CGTX revenue and earnings growth
CGTX EPSQ3 2026-$0.04
CGTX diluted EPS was -$0.04 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.06 a year earlier. For the full fiscal 2025 it was -$0.32.
CGTX free cash flowQ3 2026-$3.26M
CGTX free cash flow was -$3.26M in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2024 it was -$28.48M, compared with -$16.16M in fiscal 2023.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $37.19M | $41.68M | $37.20M | $30.32M | $18.57M | $12.89M |
| Selling, general and admin | $10.61M | $12.29M | $13.53M | $13.23M | $10.03M | $4.52M |
| Operating income | -$47.80M | -$53.97M | -$50.72M | -$43.55M | -$28.60M | -$17.41M |
| Income tax | $0 | $0 | $0 | $0 | $0 | - |
| Net income | -$23.49M | -$33.97M | -$25.79M | -$21.40M | -$11.72M | -$7.84M |
| EPS, basic | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$23.76 |
| EPS, diluted | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$23.76 |
| Diluted shares | 72.8M | 39.7M | 30.0M | 23.6M | 5.2M | 508,112 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $36.81M | $25.01M | $29.92M | $41.56M | $54.72M | $5.19M |
| Current assets | $47.99M | $29.55M | $34.22M | $47.65M | $58.99M | $6.91M |
| Total assets | $48.39M | $30.23M | $35.16M | $50.42M | $59.14M | $7.12M |
| Current liabilities | $13.92M | $11.14M | $10.17M | $7.79M | $7.86M | $3.25M |
| Long-term debt | - | - | - | - | - | $12.41M |
| Total debt | - | - | - | - | - | $12.41M |
| Total liabilities | $14.12M | $11.48M | $10.69M | $10.18M | $7.86M | $19.93M |
| Shareholders' equity | $34.27M | $18.75M | $24.47M | $40.25M | $51.27M | -$68.18M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$24.59M | -$28.47M | -$16.02M | -$18.53M | -$3.63M | -$3.43M |
| Capital expenditures | - | $4.0K | $147.0K | $171.0K | $27.0K | $10.0K |
| Free cash flow | - | -$28.48M | -$16.16M | -$18.70M | -$3.66M | -$3.44M |
| Investing cash flow | $9.0K | -$4.0K | -$147.0K | -$171.0K | -$27.0K | -$10.0K |
| Financing cash flow | $36.57M | $23.57M | $4.52M | $5.55M | $53.20M | $5.76M |
| Stock-based compensation | $2.09M | $3.75M | $4.35M | $3.57M | $5.18M | $475.0K |
| Depreciation and amortization | $36.0K | $107.0K | $96.0K | $83.0K | $93.0K | $98.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $5.12M | $5.10M | $6.12M | $11.15M | $3.77M | $11.48M | $10.79M | $8.15M | $11.39M | $11.58M | $10.55M | $11.60M |
| Selling, general and admin | $2.25M | $2.64M | $2.70M | $2.52M | $2.60M | $2.50M | $2.99M | $2.57M | $3.07M | $3.10M | $3.55M | $3.59M |
| Operating income | -$7.38M | -$7.74M | -$8.82M | -$13.67M | -$6.38M | -$13.98M | -$13.78M | -$10.72M | -$14.46M | -$14.68M | -$14.10M | -$15.19M |
| Net income | -$4.14M | -$3.93M | -$4.57M | -$3.34M | -$4.93M | -$6.73M | -$8.48M | -$7.84M | -$9.94M | -$7.04M | -$9.15M | -$8.14M |
| EPS, basic | -$0.04 | -$0.04 | -$0.05 | - | -$0.06 | -$0.11 | -$0.14 | - | -$0.25 | -$0.18 | -$0.27 | -$0.27 |
| EPS, diluted | -$0.04 | -$0.04 | -$0.05 | - | -$0.06 | -$0.11 | -$0.14 | - | -$0.25 | -$0.18 | -$0.27 | -$0.27 |
| Diluted shares | 95.1M | 90.6M | 89.2M | - | 78.0M | 63.7M | 61.8M | - | 40.4M | 40.1M | 33.7M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.76M | $34.01M | $31.13M | $36.81M | $39.33M | $10.74M | $16.43M | $25.01M | $22.01M | $28.53M | $34.67M | $29.92M |
| Current assets | $34.24M | $38.30M | $35.81M | $47.99M | $42.88M | $19.05M | $22.87M | $29.55M | $26.83M | $33.55M | $37.97M | $34.22M |
| Total assets | $34.80M | $38.90M | $36.14M | $48.39M | $43.40M | $19.62M | $23.50M | $30.23M | $27.58M | $34.37M | $38.85M | $35.16M |
| Current liabilities | $5.13M | $5.45M | $6.05M | $13.92M | $6.65M | $12.36M | $10.95M | $11.14M | $12.71M | $10.92M | $9.50M | $10.17M |
| Total liabilities | $5.53M | $5.87M | $6.23M | $14.12M | $6.87M | $12.59M | $11.23M | $11.48M | $13.10M | $11.36M | $9.99M | $10.69M |
| Shareholders' equity | $29.28M | $33.02M | $29.91M | $34.27M | $36.53M | $7.03M | $12.27M | $18.75M | $14.48M | $23.01M | $28.86M | $24.47M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.26M | -$3.05M | -$5.54M | -$3.44M | -$5.65M | -$5.62M | -$9.88M | -$8.38M | -$6.85M | -$6.00M | -$7.24M | -$5.46M |
| Capital expenditures | $0 | - | - | - | - | - | - | $1.0K | $0 | - | - | $30.0K |
| Free cash flow | -$3.26M | - | - | - | - | - | - | -$8.38M | -$6.85M | - | - | -$5.49M |
| Investing cash flow | $0 | - | - | - | - | - | - | -$1.0K | $0 | - | - | -$30.0K |
| Financing cash flow | -$28.0K | $6.61M | -$233.0K | $605.0K | $33.92M | $752.0K | $1.30M | $11.38M | $329.0K | -$138.0K | $11.99M | $2.44M |
| Stock-based compensation | $348.0K | $319.0K | $330.0K | $358.0K | $522.0K | $621.0K | $586.0K | $534.0K | $896.0K | $1.15M | $1.17M | $1.07M |
| Depreciation and amortization | - | - | - | $14.0K | $15.0K | - | - | $27.0K | $27.0K | $26.0K | $27.0K | $27.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.68 | 7.03 | 5.92 | 3.45 | 6.44 | 1.54 | 2.09 | 2.65 | 2.11 | 3.07 | 4.00 | 3.37 |
Source: XBRL data Cognition Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CGTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CGTX | - | - | -$15.99M | - | $65.3M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
CGTX FAQ
4 questionsIs CGTX profitable?
No. Cognition Therapeutics Inc. reported a net loss of $15.99M for the twelve months ended Sep 30, 2026.How much cash and debt does CGTX have?
Cognition Therapeutics Inc. reported $30.76M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did CGTX last report financial results?
The latest statements here come from Cognition Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this CGTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Cognition Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.